Evotec Secures $2.5 Million Grant for Tuberculosis Treatment Development

Evotec SE has been awarded a $2.5 million grant by The Gates Foundation to advance next-generation tuberculosis (TB) treatments. This funding extends an ongoing collaboration aimed at developing shorter and more effective TB drug regimens, addressing resistance issues with current therapies.

The partnership leverages Evotec’s advanced translational platforms to create new treatment options. The grant supports research for improved TB therapies, crucial for reducing drug-resistant TB cases. In 2021, TB affected 10.6 million people, with 450,000 cases resistant to first-line treatments, highlighting the need for better drugs.

Dr. Cord Dohrmann from Evotec expressed commitment to this initiative, which promises significant contributions to global health through innovative TB regimens.